Limited Offer
Emerging Targets and Therapeutics in the Treatment of Psychostimulant Abuse
- 1st Edition, Volume 69 - January 29, 2014
- Editor: Linda P. Dwoskin
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 4 2 0 1 1 8 - 7
- eBook ISBN:9 7 8 - 0 - 1 2 - 4 2 0 1 7 7 - 4
This new volume of Advances in Pharmacology presents the emerging targets and therapeutics in the treatment of psychostimulant abuse. With a variety of chapters and the best author… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote- Contributions from the best authors in the field
- An essential resource for pharmacologists, immunologists, and biochemists
Pharmacologists, immunologists, and biochemists
Preface
Contributors
Chapter One: Glial Modulators as Potential Treatments of Psychostimulant Abuse
Abstract
1 Introduction
2 Molecular Biology and Physiology of the Glia
3 In Vivo Evidence that Modulating Glia and Neuroinflammation Provide Pharmacotherapeutic Possibilities for Psychostimulant Abuse
4 Ongoing or Planned Clinical Studies Examining Glial Modulators in the Treatment of Psychostimulant Abuse
5 Conclusion
Conflict of Interest
Chapter Two: The Vesicular Monoamine Transporter-2
Abstract
1 Methamphetamine Addiction
2 Methamphetamine: Mechanism of Action
3 Identification and Classification of Vesicular Monoamine Transporters
4 VMAT2 Function
5 VMAT2 Binding Sites
6 Aberrant VMAT2 Expression and Function
7 Conclusion
Conflict of Interest
Acknowledgments
Chapter Three: Customizing Monoclonal Antibodies for the Treatment of Methamphetamine Abuse
Abstract
1 Introduction
2 METH Mechanisms of Action, Toxicity, and Current Therapies
3 Therapeutic Monoclonal Antibodies to Counteract METH Effects
4 Predicting Therapeutic Effectiveness
5 METH Metabolism and Pharmacokinetics: Choosing the Appropriate Animal Testing Model
6 The Role of Affinity, Binding Capacity, and In Vivo Modifications in mAb Function
7 Hapten Design for Improved Target Specificity and mAb Functionality
8 Relationship Between Hapten Structure and mAb Function: Application to Other Antibody Forms
9 Antibody Form and Duration of Action
10 Conclusion
Conflict of Interest
Acknowledgments
Chapter Four: Monoamine Transporter Inhibitors and Substrates as Treatments for Stimulant Abuse
Abstract
1 Introduction
2 Operant Behavior in Medication Development
3 Monoamine Transporters as Molecular Targets for Medication Development
4 Evaluation of Monoamine Transporter Inhibitors and Substrates on Abuse-Related Effects of Psychostimulants
5 Conclusion
Conflict of Interest
Acknowledgments
Chapter Five: Bupropion and Bupropion Analogs as Treatments for CNS Disorders
Abstract
1 Introduction
2 Metabolism of Bupropion
3 Mechanism of Bupropion Therapeutic Properties
4 Animal Behavioral Studies of Bupropion
5 Clinical Studies with Bupropion
6 Bupropion nAChR Binding Site
7 Bupropion and Hydroxybupropion Analog Clinical Development
8 Conclusion
Conflict of Interest
Acknowledgments
Chapter Six: The Role of Guanfacine as a Therapeutic Agent to Address Stress-Related Pathophysiology in Cocaine-Dependent Individuals
Abstract
1 Introduction
2 Guanfacine as a Medication for Substance Abuse Compared with Other Alpha-2 Adrenergic Agonists
3 Other Potential Anxiolytics and Cognitive Enhancers
4 Long-Term Maintenance of Guanfacine
5 Conclusion
Conflict of Interest
Chapter Seven: Beyond Small-Molecule SAR
Abstract
1 Introduction
2 D3-Selective Drug Design Using Small-Molecule SAR
3 Clinical Studies Targeting the D3 Receptor in the Treatment of Addiction
4 The Structural Basis of D3 over D2 Receptor Selectivity and the Future of Rational Drug Design for D3 Receptor-Selective Ligands
5 Conclusion
Conflict of Interest
Acknowledgments
Chapter Eight: Dopamine D4 Receptors in Psychostimulant Addiction
Abstract
1 Introduction
2 DRD4 and Psychostimulant Addiction
3 Conclusion
Conflict of Interest
Acknowledgments
Chapter Nine: Sigma (σ) Receptors as Potential Therapeutic Targets to Mitigate Psychostimulant Effects
Abstract
1 Introduction
2 Background on σ Receptors
3 Cocaine and σ Receptors
4 Methamphetamine and σ Receptors
5 Clinical Implications
6 Conclusion
Conflict of Interest
Acknowledgments
Chapter Ten: Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence
Abstract
1 Introduction
2 Opioids Used to Treat Drug and Alcohol Dependence: Preclinical and Clinical Evidence
3 Mechanistic and In Vitro Characterization of Mixed μ/κ Agonists
4 Conclusion
Conflict of Interest
Acknowledgments
Chapter Eleven: The Combination of Metyrapone and Oxazepam for the Treatment of Cocaine and Other Drug Addictions
Abstract
1 Introduction
2 Stress and Addiction
3 Cocaine and Benzodiazepines
4 Stress and Cocaine Reinforcement
5 Stress and Relapse
6 Rationale for Testing Drug Combinations
7 Our Hypothesis Changes
8 Medial Prefrontal Cortex and Cocaine
9 Neurosteroids and the Combination of Metyrapone and Oxazepam
10 Conclusion
Conflict of Interest
Chapter Twelve: Salvinorin A Analogs and Other Kappa-Opioid Receptor Compounds as Treatments for Cocaine Abuse
Abstract
1 Introduction
2 Kappa-Opioid Receptors and the Endogenous Opioid System
3 Kappa-Opioid Regulation of Dopamine Systems
4 Effects of Drugs of Abuse on the Kappa-Opioid System
5 Effects of Kappa-Opioid Receptor Agonists on Drug Addiction
6 Animal Studies with Sal A
7 Effects of Sal A on Depression
8 Antidepressive Effects of Sal A
9 Prodepressive Effects of Sal A
10 Signaling Pathways Regulated by Sal A
11 Pharmacokinetics of Sal A
12 Sal A Analogs
13 Conclusion
Conflict of Interest
Chapter Thirteen: Nicotinic Receptor Antagonists as Treatments for Nicotine Abuse
Abstract
1 Introduction
2 Current Smoking Cessation Therapies that Target nAChRs
3 Emerging Potential Therapeutics for Treatment of Tobacco Dependence
4 Small-Molecule Surrogates of α-CtxMII as Smoking Cessation Agents
5 Monoquaternary Ammonium Salts Derived from N-Methylnicotinium Ion as Nicotinic Receptor Antagonists
6 Conclusion
Conflict of Interest
Acknowledgments
Chapter Fourteen: New Directions in Nicotine Vaccine Design and Use
Abstract
1 Introduction
2 Status of First-Generation Nicotine Vaccines
3 Limitations of First-Generation Nicotine Vaccines
4 Limitations of Vaccination as a General Strategy for Treating Nicotine Addiction
5 Design of Nicotine Vaccines
6 Strategies for Improving Vaccine Efficacy
7 Alternatives to Vaccination
8 Translational Considerations
9 Conclusion
Conflict of Interest
Acknowledgments
Chapter Fifteen: Bath Salts, Mephedrone, and Methylenedioxypyrovalerone as Emerging Illicit Drugs That Will Need Targeted Therapeutic Intervention
Abstract
1 Introduction
2 PIA Analogs: Nomenclature and Pharmacological Assays
3 Cathinone Analogs: Historical Perspectives
4 Amphetamine (i.e., Phenylisopropylamine) Analogs
5 Synthetic Cathinones: Specific Agents
6 Synthetic Cathinones: Mechanisms of Action and Behavioral Studies
7 Synthetic Cathinones: Human Studies
8 Conclusion
Conflict of Interest
Acknowledgments
Index
- No. of pages: 656
- Language: English
- Edition: 1
- Volume: 69
- Published: January 29, 2014
- Imprint: Academic Press
- Hardback ISBN: 9780124201187
- eBook ISBN: 9780124201774
LD